News related to Serentil (Mesoridazine) and/or conditions it is approved for
New Study Shows Potential Of Rational Drug Design In Schizophrenia
Source: Health News from Medical News Today [2008.12.01]
In one of the first instances of targeted drug design in psychiatric treatment, University of Pittsburgh researchers have found an experimental agent that shows promise in addressing working memory impairments that occur in the schizophrenia. The study breaks new ground in the strategy used to develop new pharmacological treatments for schizophrenia, explained David Lewis, M.D.
Schering-Plough Unveils Top-Line Study Results For SAPHRIS(TM) (asenapine) Demonstrating Efficacy In Long-Term Schizophrenia Relapse Prevention
Source: Schizophrenia News From Medical News Today [2008.11.25]
Schering-Plough Corporation (NYSE: SGP) revealed top-line results of a long-term Phase III clinical study of its psychopharmacologic agent SAPHRIS(TM) (asenapine) demonstrating efficacy and safety in preventing relapse of schizophrenia. In this trial, asenapine was statistically significantly more effective than placebo in preventing relapse, as measured by the primary endpoint of the trial estimated through Kaplan-Meier curves.
Memory Pharmaceuticals Achieves Enrollment Goal For Phase 2 Study Of MEM 3454 In Cognitive Impairment Associated With Schizophrenia
Source: Schizophrenia News From Medical News Today [2008.11.20]
Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced that it has achieved the enrollment goal for its Phase 2 trial of R3487/MEM 3454, its lead alpha-7 nicotinic receptor agonist, in cognitive impairment associated with schizophrenia (CIAS). The Company has randomized 212 patients in the Phase 2 trial, triggering a $5.0 million payment from its partner Roche. Memory Pharmaceuticals expects to report top-line results from the trial by the end of April 2009.
Compound Tied to Cognitive Deficits in Schizophrenia
Source: MedicineNet Schizophrenia Specialty [2008.11.20]
Title: Compound Tied to Cognitive Deficits in Schizophrenia
Category: Health News
Created: 11/20/2008 2:00:00 AM
Last Editorial Review: 11/20/2008
Schizophrenia: Brain Compound 'Throws Gasoline Onto The Fire'
Source: Schizophrenia News From Medical News Today [2008.11.19]
New research has traced elevated levels of a specific compound in the brain to problem-solving deficits in patients with schizophrenia. The finding suggests that drugs used to suppress the compound, called kynurenic acid, might be an important supplement to antipsychotic medicines, as these adjuncts could be used to treat the disorder's most resistant symptoms - cognitive impairments.
World's Leading Experts In Schizophrenia To Meet At 25th Annual Pittsburgh Schizophrenia Conference Nov. 21
Source: Schizophrenia News From Medical News Today [2008.11.14]
Internationally renowned experts in schizophrenia and other psychotic disorders, researchers and clinicians, patients and their families and friends, will gather in Pittsburgh to discuss the latest in research and clinical advances at the 25th Annual Pittsburgh Schizophrenia Conference to be held Friday, Nov. 21 at the Sheraton Station Square, Pittsburgh.
Schizophrenia And Bipolar Disorder - Clinical Feasibility Of Once-a-Day Ziprasidone
Source: Bipolar News From Medical News Today [2008.11.13]
Lipocine Inc., a specialty pharmaceutical company that uses clinically validated proprietary technologies to address key unmet drug delivery and therapeutic needs, today announced the successful completion of a clinical study that establishes feasibility of the first once-a-day dosing product for Ziprasidone, a leading treatment for schizophrenia and bipolar disorder. - Schizophrenia affects 1% of the population and bipolar disorder affects 5.7M adults in the US*.
Brain Function In Schizophrenia May Be Altered By Interaction Between Gene Variants
Source: Schizophrenia News From Medical News Today [2008.11.10]
A collaborative study led by investigators from Massachusetts General Hospital (MGH) is giving what may be the first look at how interactions between genes underlie a key symptom of schizophrenia, impaired working memory. Functional imaging studies reveal how a combination of common variants in two genes is associated with reduced activity of important brain structures in schizophrenia patients but not in normal controls.
New Target In Brain For Treating Schizophrenia Identified By Pitt Researchers
Source: Schizophrenia News From Medical News Today [2008.11.06]
Research from the University of Pittsburgh could expand the options for controlling schizophrenia by identifying a brain region that responds to more than one type of antipsychotic drug. The findings illustrate for the first time that the orbitofrontal cortex could be a promising target for developing future antipsychotic drugs - even those that have very different mechanisms of action. The study will be published during the week of Nov.
Glutamate:Too Much Of A Good Thing In Schizophrenia?
Source: Schizophrenia News From Medical News Today [2008.10.31]
Is schizophrenia a disorder of glutamate hyperactivity or hypoactivity? While the predominant hypothesis for many years was that schizophrenia was a glutamate deficit disorder, there is growing evidence of glutamate hyperactivity as well. The study by Karlsson et al., appearing in the November 1st issue of Biological Psychiatry, reinforces this point with new data about the impact of deleting the gene for the glutamate transporter EAAT1.
Anti-Inflammatory Medications May Become A Treatment For Schizophrenia
Source: Schizophrenia News From Medical News Today [2008.10.28]
Many of the structural and neurochemical features of schizophrenia are present long before the full syndrome of schizophrenia develops. What processes tip the balance between the ultra-high risk states and the development of schizophrenia? One candidate mechanism is cerebral inflammation, studied by Dr. Bart van Berckel and colleagues in the November 1st issue of Biological Psychiatry.
Association Between Lower Levels Of A Protein Measured At Birth And Increased Risk Of Developing Schizophrenia As An Adult
Source: Schizophrenia News From Medical News Today [2008.10.28]
Complications during pregnancy and birth, such as birth hypoxia - the shortage of oxygen in the body - are associated with an increased risk for schizophrenia. However, it is not clear why hypoxia increases the risk for schizophrenia. The November 1st issue of Biological Psychiatry includes an article by researchers who show that the presence of a specific indicator of fetal distress following hypoxia was more likely to be present among people who later develop schizophrenia.
New Brain Link As Cause Of Schizophrenia
Source: Schizophrenia News From Medical News Today [2008.10.28]
A lack of specific brain receptors has been linked with schizophrenia in new research by scientists at Newcastle University. In work published in the Proceedings of the National Academy of Sciences, the team has found that NMDA receptors are essential in modifying brain oscillations - electrical wave patterns - which are altered in patients with schizophrenia.
Scientists ID 3 New Candidate Genes for Schizophrenia
Source: MedicineNet Schizophrenia Specialty [2008.10.27]
Title: Scientists ID 3 New Candidate Genes for Schizophrenia
Category: Health News
Created: 10/25/2008 2:00:00 AM
Last Editorial Review: 10/27/2008
Asenapine Meets Primary Endpoint In Long-Term Schizophrenia Relapse Prevention Trial
Source: Schizophrenia News From Medical News Today [2008.10.24]
Schering-Plough Corporation (NYSE: SGP) announced that its novel psychopharmacologic agent asenapine has met the primary endpoint in a long-term schizophrenia relapse prevention trial. Asenapine, which is administered as a fast-dissolving sublingual tablet, is a psychopharmacologic compound with a unique human receptor signature.
Newer Drugs No Better Than Older Ones for Childhood Schizophrenia
Source: MedicineNet Muscle Cramps Specialty [2008.09.16]
Title: Newer Drugs No Better Than Older Ones for Childhood Schizophrenia
Category: Health News
Created: 9/16/2008 2:00:00 AM
Last Editorial Review: 9/16/2008
Seroquel XL (Quetiapine Prolonged Release): A Once Daily Formulation For Bipolar Mania And Schizophrenia Launches Today, UK
Source: Bipolar News From Medical News Today [2008.09.15]
Today, Seroquel XL (quetiapine prolonged release), a new once daily formulation for schizophrenia and manic episodes associated with bipolar disorder, has become available in the UK.1 AstraZeneca has developed the new formulation of its atypical antipsychotic treatment to meet the needs of patients for whom a once daily dose is preferred and/or for whom1 effective control of symptoms is important.
Hormone Therapy for Schizophrenia?
Source: MedicineNet Bipolar Disorder Specialty [2008.08.05]
Title: Hormone Therapy for Schizophrenia?
Category: Health News
Created: 8/5/2008
Last Editorial Review: 8/5/2008
Schizophrenia Yields Some Genetic Secrets
Source: MedicineNet Autism Specialty [2008.07.31]
Title: Schizophrenia Yields Some Genetic Secrets
Category: Health News
Created: 7/31/2008 2:00:00 AM
Last Editorial Review: 7/31/2008
Monthly Shot Treats Schizophrenia
Source: MedicineNet aripiprazole Specialty [2008.05.08]
Title: Monthly Shot Treats Schizophrenia
Category: Health News
Created: 5/8/2008
Last Editorial Review: 5/8/2008
New Drugs No Better Than Older Ones for Schizophrenia
Source: MedicineNet haloperidol Specialty [2008.03.31]
Title: New Drugs No Better Than Older Ones for Schizophrenia
Category: Health News
Created: 3/29/2008 2:00:00 AM
Last Editorial Review: 3/31/2008
Schizophrenia
Source: MedicineNet aripiprazole Specialty [2008.02.21]
Title: Schizophrenia
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 2/21/2008
Zyprexa in schizophrenia shown to prevent brain loss
Source: The Doctors Lounge - Psychiatry
Zyprexa (olanzapine) was found to decrease brain loss in schizophrenia patients according to the Archives of General Psychiatry.
Low Childhood IQ Tied to Risk of Later Mental Disorders (HealthDay)
Source: Y! Health News Search RSS Feed [2008.12.01]
HealthDay - MONDAY, Dec. 1 (HealthDay News) -- Children with lower IQ have an
increased risk of developing schizophrenia, depression, generalized
anxiety disorder and other psychiatric problems as adults, a new study
that spanned more than three decades shows.
Treatment With Paliperidone ER Significantly Improves Symptoms Of Schizoaffective Disorder, Study
Source: Schizophrenia News From Medical News Today [2008.11.03]
Patients with schizoaffective disorder receiving paliperidone extended release tablets (paliperidone ER) for six weeks showed a significant improvement in their symptoms, according to a new study presented today at the U.S. Psychiatric & Mental Health Congress in San Diego, Calif.(1) In addition, safety findings were similar to published studies of paliperidone ER in the treatment of schizophrenia.
Measurement And Reporting Of Duration Of Untreated Psychosis
Source: Schizophrenia News From Medical News Today [2008.10.30]
This study investigates the duration of untreated psychosis (DUP) in relation to demographic, illness and methodological factors using a systematic review of published studies of DUP and available DUP distributions. The results showed that DUP is shorter in samples that include patients with affective-psychosses, and longer in samples with a greater proportion of patients with schizophrenia.
Global Psychiatrists Unite To Improve Services In Mental Health
Source: Bipolar News From Medical News Today [2008.09.19]
Thirty seven medical experts in psychiatry from across the world have called on the medical community to take urgent action to optimize services for people with a diagnosis of severe mental illness such as schizophrenia or bipolar disorder(i). Professor W.
AstraZeneca's Seroquel XL, Once Daily Formula, Now Available For UK Patients
Source: Bipolar News From Medical News Today [2008.09.18]
Seroquel XL (quetiapine prolonged release) a new, once daily formulation for schizophrenia and manic episodes associated with bipolar disorder, has today become available in the UK.[1] The new formulation was developed to address the needs of patients who require effective control of symptoms in a once daily rather than twice daily tablet.
|
